Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Gains from Investment Securities: 2015-2024

Historic Gains from Investment Securities for Viking Therapeutics (VKTX) over the last 10 years, with Dec 2024 value amounting to $4.7 million.

  • Viking Therapeutics' Gains from Investment Securities fell 99.79% to $10,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $42.1 million, marking a year-over-year increase of 765.78%. This contributed to the annual value of $4.7 million for FY2024, which is 9.80% down from last year.
  • As of FY2024, Viking Therapeutics' Gains from Investment Securities stood at $4.7 million, which was down 9.80% from $5.2 million recorded in FY2023.
  • Over the past 5 years, Viking Therapeutics' Gains from Investment Securities peaked at $5.2 million during FY2023, and registered a low of $3.4 million during FY2020.
  • Over the past 3 years, Viking Therapeutics' median Gains from Investment Securities value was $5.2 million (recorded in 2022), while the average stood at $5.0 million.
  • Per our database at Business Quant, Viking Therapeutics' Gains from Investment Securities soared by 30.65% in 2020 and then dropped by 9.80% in 2024.
  • Yearly analysis of 5 years shows Viking Therapeutics' Gains from Investment Securities stood at $3.4 million in 2020, then grew by 21.26% to $4.1 million in 2021, then climbed by 26.17% to $5.2 million in 2022, then climbed by 1.76% to $5.2 million in 2023, then fell by 9.80% to $4.7 million in 2024.